Mezigdomide, a novel cereblon E3 ligase modulator (CELMoD), demonstrates a more favorable safety profile than traditional immunomodulatory drugs (IMiDs) in treating relapsed/refractory multiple myeloma. According to Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, the drug’s potential to spare patients from gastrointestinal toxicity while restoring immune function may extend treatment duration and improve clinical outcomes.
How Do CELMoDs Differ from Traditional IMiDs?
Traditional IMiDs like lenalidomide (Revlimid) and pomalidomide (Pomalyst) are often associated with long-term gastrointestinal (GI) toxicity, which can force clinicians to reduce doses or discontinue therapy. In contrast, Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, note that CELMoDs such as mezigdomide appear to avoid these specific GI side effects.
This improved tolerability is vital. By keeping patients on therapy for longer periods, clinicians expect to see better progression-free survival rates. The shift represents a move toward agents that can be managed more effectively in a clinical setting.
In the phase 3 SUCCESSOR-2 trial (NCT05552976), the rate of opportunistic infection for patients treated with mezigdomide was under 2%.
Managing Neutropenia and Infection Risks
While neutropenia remains a factor with mezigdomide, Paul Richardson, MD, distinguishes it from the broader bone marrow suppression seen with other therapies. According to Paul Richardson, MD, mezigdomide-related neutropenia is a “differentiation effect” rather than a stem cell effect. He emphasizes that proactive use of growth factor support has effectively mitigated this risk.
Clinical data supports this manageable profile. Paul Richardson, MD, reports that grade 3 infection rates in mezigdomide studies hover between 25% and 30%. This is significantly lower than the 60% to 70% rate often observed with T-cell–redirecting therapies, such as bispecific antibodies or CAR T-cell therapy.
The Role of Immune Restoration
Beyond its direct tumor-killing capabilities, mezigdomide appears to improve the overall fitness of a patient’s immune system. Muhamed Baljevic, MD, FACP, explains that the drug reduces immune exhaustion by targeting markers such as TIGIT, KLRG-1, and ICOS. This restoration of T-cell function may explain the lower incidence of opportunistic infections compared to other potent myeloma treatments.
| Therapy Type | Grade 3 Infection Rate |
|---|---|
| Mezigdomide | 25% – 30% |
| Bispecifics/CAR T-cell | 60% – 70% |
Future Trends in Combination Therapy
The future of mezigdomide lies in combination strategies. Early data from the phase 1/2 MELT-MM trial (NCT06645678) shows promising results when combining mezigdomide with elranatamab. This combination yielded a 90% response rate and a 75% complete response rate in a heavily pretreated, high-risk population.
Muhamed Baljevic, MD, FACP, notes that both iberdomide and mezigdomide are currently being developed for use both before and after CAR T-cell therapy. Researchers believe these agents could eventually be used to “shorten and fix” treatment durations for patients receiving bispecific antibodies, leveraging the CELMoD’s ability to reverse immune exhaustion.
When evaluating new regimens, always look at the trial’s protocol regarding growth factor support. Proactive management, rather than reactive dosing, is currently the approach for optimizing outcomes in mezigdomide trials.
Frequently Asked Questions
- How does mezigdomide compare to older IMiDs? Mezigdomide is a CELMoD that appears to avoid the chronic gastrointestinal toxicity associated with lenalidomide and pomalidomide.
- Is neutropenia a major concern with mezigdomide? While it occurs, researchers characterize it as a manageable differentiation effect that responds well to proactive growth factor support.
- What is the primary benefit of the MELT-MM trial combination? The combination of mezigdomide and elranatamab has shown high response rates in high-risk, pretreated populations while maintaining a favorable safety profile.
Are you interested in the latest developments in multiple myeloma research? Subscribe to our newsletter to receive updates on emerging clinical trials and new therapeutic classes.
